Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (≤ 1 cm) stage III and IV ovarian cancer

European Journal of Gynaecological Oncology

Volumn 19, Issue 1, 1998, Pages 5-10

  Piver, M S ^a   Eltabbakh, G H ^a   Hempling, R E ^a   Recio, F O ^a   Blumenson, L E ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NAUSEA; NEPHROTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0031984910     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)